Patheon and Solvias partner to offer integrated development services

This alliance combines Patheon’s experience and expertise in formulation development with Solvias’s reputation of excellence in pre-formulation and solid state chemistry.

The partnering of Patheon and Solvias will provide customers flexible and integrated early development services including active pharmaceutical ingredient characterization, salt selection and co-crystallization, polymorphism screening, solubility determination, excipient compatibility and formulation.

Patheon’s Quick to Clinic program will be implemented for rapid Phase I development and to optimize programs for special molecules such as those with low solubility or challenging solid-state properties.

Wes Wheeler, CEO and president of Patheon, said: “Patheon’s vision is to be the best provider of services. This alliance with Solvias is an example of how Patheon is committed to providing and expanding these turnkey solutions for the most integrated, value added service offering for our customers.”